NCT06648772: An ongoing trial by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
This trial is ongoing. It must report results 1 month, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06648772 |
|---|---|
| Title | A Multicenter, Randomized, Double-blind, Vehicle-controlled Phase 3 Clinical Study To Evaluate The Efficacy and Safety Of Roflumilast Cream 0.3% (Zoryve®) in the Treatment of Plaque Psoriasis In China |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 14, 2024 |
| Completion date | June 28, 2025 |
| Required reporting date | June 28, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 11, 2026 |
| Days late | None |